Coinbase Global, Inc. vs Moderna, Inc. — how do they compare? Coinbase Global, Inc. trades at $148.11 (market cap $39.20B), while Moderna, Inc. trades at $63.23 (market cap $24.18B). The key difference: Coinbase Global, Inc. is the larger of the two by market cap, and Moderna, Inc. is trading nearer its 52-week high, Coinbase Global, Inc. nearer its low. Which is the better fit depends on your goals.
| COIN | MRNA | |
|---|---|---|
Market Cap | $39.20B | $24.18B |
Sector | Technology | Health |
52-Week High | $387.27 | $81.80 |
52-Week Low | $141.09 | $22.36 |
Enterprise Value | $36.85B | $20.33B |
Signals from Pluang's Aura AI — not financial advice
COIN stock trades at $148.68, down 3.2% in the last session amid bearish technical signals and recent earnings misses. The company reported Q2 2026 revenue and EPS below expectations, marking the third consecutive quarterly loss despite achieving record 10.3% global trading volume share. Analyst sentiment remains mixed with 55% buy ratings but a Zacks strong sell designation on August 6, 2026. Technical indicators show bearish momentum with support at $141 and resistance at $152.
The outlook remains challenging with projected 2026 revenue decline to $6.3B and net loss of $988M. While the company maintains strong cash flow from operations ($2.4B in 2025) and is expanding into AI payment solutions, persistent earnings misses and crypto market volatility pose significant risks. The consensus price target of $207.20 suggests 39% upside potential if execution improves.
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Trailing returns across standard periods
Latest headlines on both assets
Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.
Read more on COIN →Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →